查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1351102

2030 年基因治疗市场预测：按细分市场和地区分類的全球分析

Gene Therapy Market Forecasts to 2030 - Global Analysis By Vector (Non-Viral Vectors & Viral Vectors), Gene Type (Antigen, Cytokine, Tumor Suppressor & Other Gene Types), Delivery Method (In Vivo & Ex Vivo), Application, End User & By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球基因治疗市场规模为 88 亿美元，预计预测期内年复合成长率为 20.6%，到 ​​2030 年将达到 326.6 亿美元。

人类基因疗法是治疗方法。他们的目的是为了治疗目的而改变或调节活细胞的基因表现或生物特性。惰性无法正常运作的致病基因、用健康基因的副本取代致病基因、将新的或修饰的基因引入体内来治疗疾病，这些都是基因治疗的一些方法。正在研究使用基因疗法的产品来治疗癌症、遗传性疾病和感染疾病疾病。

根据 ACS 的《2022 年癌症事实与数据》，2022 年美国将报告约 1,918,030 例新癌症病例和 609,360 例癌症死亡。目前多种基因治疗策略被用于治疗癌症。

新基因治疗技术

借助基因疗法，以前只能暂时治疗的疾病现在可以永久治疗。基因疗法长期以来一直失败，但近年来，已经报导了成功且长期的治疗方法。对于多种遗传疾病，包括血液异常、免疫力缺乏、视力障碍、神经细胞再生、代谢障碍和几种癌症，已经取得了有希望的结果。基因疗法有潜力成为一种个体化治疗方法，可以更特异性治癒各种疾病，同时副作用更少。基因疗法是将遗传物质引入患者体内以治疗疾病或至少改善临床状况，正在推动市场成长。

基因治疗产品受到严格法规

在全球范围内，基因疗法的使用正在迅速扩大。这是因为高龄化，许多慢性疾病是可以透过早期发现和及时治疗来避免的。同样，参与企业必须遵守一系列法规，以获得当局的许可在某个地区推出其产品。任何程序中最困难的挑战之一就是遵守这些严格的限制。基因治疗药物在不同国家有不同程度的上市前核准。

神经系统和肿瘤疾病的比例增加

罕见的遗传疾病在世界各地的人们中变得越来越常见。国家罕见疾病组织 (NORD) 估计，在美国，每年万分之一的比例是由脊髓性肌肉萎缩症引起的。专业经历了技术发展，使以前被认为无法治癒的疾病变得更容易治癒。另一方面，世界上最常见的疾病之一是癌症。这些基因疗法有助于预防由于前几代遗传的基因突变而特别容易患某些癌症的人的疾病。

昂贵的治疗费用

为了治疗疾病，患者的基因组可能会被改变、删除或添加，作为称为基因治疗的新医疗程序的一部分。儘管基因治疗仍处于起步阶段，但人们对治疗甚至治癒先前的疑难杂症抱持着很大的期望。在许多国家，基因治疗的费用在很大程度上仍然法规，是根据具体情况确定的，通常是一次性支付。

COVID-19 的影响：

COVID-19 对基因治疗市场的整体影响仍然有利，因为前往医院和诊所接受基因治疗 (ICI) 的癌症患者数量有所减少，导致对基因治疗产品的需求减少。例如，NCBI预测，到2020年，美国癌症患者数量将减少约50%，在COVID-19期间，基因治疗产品的市场需求也将减少约50%。

预计病毒载体部分在预测期内将是最大的

控制病毒载体表达治疗基因的能力使其成为改变特定细胞类型和组织的最有效的基因转移方法，因此预计病毒载体片段将享有良好的生长。目前正在研究几种类型的病毒用于将基因引入细胞以进行临时或永久转基因表达的潜力。为了逃避受感染宿主的免疫监视，病毒已经进化到能够有效地将核酸传递到有限的细胞类型。这些特性使病毒作为基因治疗的基因转移载体具有吸引力，并正在推动市场成长。

预计医院领域在预测期内的年复合成长率最高。

预计医院领域在预测期内的年复合成长率最高。这是因为这些设施中的治疗方法高度可用且容易获得，这有助于普及。预计该细分市场将在整个预测期内保持主导地位。随着提供神经系统和癌症疾病最先进治疗的独立诊所的兴起，诊所市场也有望扩大。

比最大的地区

就预测期内的核准数量和销售额而言，预计北美将在预测期内占据最大的市场占有率，随着更多大小公司投资研发以创造最佳药物，该市场预计将增长。预计未来将继续扩大治疗范围。政府投资水准的增加和某些疾病罹患率的上升也推动了市场的发展。脊髓性肌肉萎缩症基金会估计，到 2020 年，美国将有 10,000 至 25,000儿童和成人受到脊髓性肌肉萎缩症的罹患，使其成为一种相当普及。这是一种疾病。

复合年复合成长率最高的地区：

预计亚太地区在预测期内的年复合成长率最高。这是由于亚太地区人口众多，医疗需求未被满足，以及在管理罕见但稳定增长的疾病方面对突破性技术的需求日益增长。由于资源容易取得、当地大型公司的存在以及政府财政支持的增加，预计亚太地区基因治疗商业应用市场将在预测期内显着扩大。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 用途分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球基因治疗市场：依载体分类

  • 非病毒载体
    • 寡核苷酸
    • 其他非病毒载体
  • 病毒载体
    • 逆转录病毒载体
    • 腺相关病毒载体
    • 慢病毒载体
    • 疱疹病毒载体
    • 其他病毒载体

第6章全球基因治疗市场：依基因类型

  • 抗原
  • 细胞因子
  • 肿瘤抑制因子
  • 自杀
  • 不足
  • 生长因子
  • 受体
  • 其他基因型

第7章全球基因治疗市场：依交付方式

  • In Vivo
  • Ex Vivo

第8章全球基因治疗市场：依用途

  • DMD（Duchenne氏肌肉失养症）
  • 神经系统疾病
  • 癌症
  • 肝病
  • 罕见疾病
  • 肿瘤性疾病
  • 急性淋巴性白血病（ALL）
  • 周边动脉疾病
  • 其他用途

第9章全球基因治疗市场：依最终用户分类

  • 癌症研究所
  • 医院
  • 研究机构
  • 其他最终用户

第10章全球基因疗法市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Amgen Inc.
  • Biogen Inc.
  • Bluebird Bio Inc.
  • Gilead Sciences Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • UniQure NV
  • Abeona Therapeutics Inc.
  • Generation Bio
  • Poseida Therapeutics
  • Astellas Pharma
  • Voyager Therapeutics Inc.
  • Jazz Pharmaceuticals, Inc
  • GlaxoSmithKline plc
  • Spark Therapeutics Inc
  • Sarepta Therapeutics
  • Orchard Therapeutics
  • Shenzhen SiBiono GeneTech
  • Shanghai Sunway Biotech Co. Ltd.
  • CRISPR Therapeutics AG
Product Code: SMRC23789

According to Stratistics MRC, the Global Gene Therapy Market is accounted for $8.80 billion in 2023 and is expected to reach $32.66 billion by 2030 growing at a CAGR of 20.6% during the forecast period. Human gene therapy is a procedure that alters a person's genes to treat or cure disease. It aims to change or regulate a gene's expression or the biological characteristics of live cells for therapeutic purpose. Inactivating a disease-causing gene that is not working correctly, replacing a disease-causing gene with a healthy copy of the gene, and introducing a new or modified gene into the body to cure a disease are some of the ways that gene therapies can operate. Products utilizing gene therapy are being investigated for the treatment of diseases including cancer, genetic disorders, and infectious diseases.

According to the ACS 'Cancer Facts & Figures 2022', around 1,918,030 new cancer cases and 609,360 deaths due to cancers are estimated to be reported in the United States in 2022. In the treatment of cancer, various gene therapy strategies are currently employed.

Market Dynamics:

Driver:

Novel gene therapy techniques

Ailments that previously only received temporary therapies now have permanent remedies because to gene therapy. Gene therapy failed for a very long time; nevertheless, in recent years, successful and long-lasting treated instances have been documented. Promising results have been reached for a wide range of genetic ailments, including blood abnormalities, immunological inadequacies, eyesight problems, nerve cell regeneration, metabolic disorders, and several cancer kinds. Gene therapy has the potential to be a personalized treatment that can "cure" a range of diseases with more specificity and fewer negative effects. Gene therapy is the practice of transferring genetic material to a patient in order to treat a disease or, at the very least, improve their clinical state which enhances the growth of the market.

Restraint:

Gene therapy products are subject to strict restrictions

Globally, the use of gene therapy is expanding quickly because to the aging population and a number of chronic diseases that can be avoided with early detection and prompt treatment. Likewise, in order to receive clearance from higher authorities for the product's introduction in an area, gene therapy market participants must go by a set of rules. One of the most challenging duties among all the procedures is adhering to these strict restrictions. Different gene therapy medicines have different pre-market approval levels depending on the nation.

Opportunity:

Increasing rates of neurological and oncological disorders

Rare genetic illnesses are becoming more common among people all over the world. The National Organization for Rare Diseases (NORD) estimates that 1 in 10,000 live births in the United States occur each year due to spinal muscular atrophy. The profession has experienced technological developments that have made it easier to cure diseases that were formerly thought to be incurable. On the other hand, one of the most common diseases in the world is cancer. These gene treatments assist individuals who are especially susceptible to developing specific forms of cancer due to genetic mutations handed down from the previous generation in preventing the disease.

Threat:

High cost of treatment

In order to treat an illness, a patient's genome may be altered, deleted, or added to as part of a novel medical procedure known as gene therapy. Gene therapy has already demonstrated significant promise for the treatment and even cure of once-intractable disorders, despite the fact that it is still in its infancy. In many countries, the cost of gene therapy is still largely unregulated and decided on a case-by-case basis, typically focused on a single upfront payment.

COVID-19 Impact:

Due to a decrease in the number of cancer patients visiting hospitals and clinics for gene therapy (ICI), which resulted in a decrease in demand for gene therapy products, COVID-19's overall impact on the market for gene therapy remained unfavorable. For instance, the NCBI estimates that the number of cancer patients in the U.S. would drop by around 50% by 2020, and that the market's demand for gene therapy products will also drop by about 50% during COVID-19.

The viral vectors segment is expected to be the largest during the forecast period

The viral vectors segment is estimated to have a lucrative growth, due to the ability to control viral vectors to express therapeutic genes makes them the most efficient method of gene transfer for altering a particular cell type or tissue. Several virus types are being researched right now for their potential to be used to transfer genes to cells for either temporary or permanent transgenic expression. In order to circumvent immune monitoring by an infected host, viruses have evolved to become extremely effective at delivering nucleic acids to a limited range of cell types. These characteristics make viruses appealing gene delivery vectors for gene therapy, thus propelling the growth of the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, as the prevalence is caused by the treatment modalities' great availability and accessibility in such institutions. Throughout the projection period, it is expected that this market segment will continue to rule. Due to the rise of independent clinics offering cutting-edge treatments for neurological and cancer disorders, the clinics market is also expected to expand.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the number of approvals and the amount of money made throughout the projected period, and the market will continue to grow as more major and small businesses make R&D expenditures in the creation of medications for optimum therapy. The market is also being driven by the governments' expanding investment levels and the rising incidence of certain ailments. The Spinal Muscular Atrophy Foundation estimates that between 10,000 and 25,000 children and adults in the United States will have spinal muscular atrophy by the year 2020, making it a reasonably prevalent condition.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the country's sizable population's unmet medical demands and rising need for breakthrough technology in the management of uncommon but steadily escalating diseases. Due to the easy access to resources, the presence of big corporations locally, and rising government funding, the Asia Pacific market for the commercial use of genetic treatments is predicted to have considerable expansion over the projected period.

Key players in the market:

Some of the key players profiled in the Gene Therapy Market include: Amgen Inc. , Biogen Inc., Bluebird Bio Inc., Gilead Sciences Inc., Novartis AG, F. Hoffmann-La Roche Ltd, UniQure NV, Abeona Therapeutics Inc., Generation Bio, Poseida Therapeutics, Astellas Pharma, Voyager Therapeutics Inc., Jazz Pharmaceuticals, Inc, GlaxoSmithKline plc, Spark Therapeutics Inc, Sarepta Therapeutics, Orchard Therapeutics, Shenzhen SiBiono GeneTech, Shanghai Sunway Biotech Co. Ltd. and CRISPR Therapeutics AG

Key Developments:

In August 2023, Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years. The results were presented in a late-breaking session at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam.

In July 2023, Biogen to Acquire Reata Pharmaceuticals, Reata has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.

In February 2023, Kite, a Gilead Company announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

Vectors Covered:

  • Non-Viral Vectors
  • Viral Vectors

Gene Types Covered:

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Other Gene Types

Delivery Methods Covered:

  • In Vivo
  • Ex Vivo

Applications Covered:

  • DMD (Duchenne Muscular Dystrophy)
  • Neurological Diseases
  • Cancer
  • Hepatological Diseases
  • Rare Diseases
  • Oncological Disorders
  • Acute Lymphoblastic Leukemia (ALL)
  • Peripheral arterial disease
  • Other Applications

End Users Covered:

  • Cancer Institutes
  • Hospitals
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gene Therapy Market, By Vector

  • 5.1 Introduction
  • 5.2 Non-Viral Vectors
    • 5.2.1 Oligonucleotides
    • 5.2.2 Other Non-Viral Vectors
  • 5.3 Viral Vectors
    • 5.3.1 Retro Viral Vectors
    • 5.3.2 Adeno-Associated Virus Vectors
    • 5.3.3 Lentiviral Vector
    • 5.3.4 Herpes Virus Vector
    • 5.3.5 Other Viral Vectors

6 Global Gene Therapy Market, By Gene Type

  • 6.1 Introduction
  • 6.2 Antigen
  • 6.3 Cytokine
  • 6.4 Tumor Suppressor
  • 6.5 Suicide
  • 6.6 Deficiency
  • 6.7 Growth factors
  • 6.8 Receptors
  • 6.9 Other Gene Types

7 Global Gene Therapy Market, By Delivery Method

  • 7.1 Introduction
  • 7.2 In Vivo
  • 7.3 Ex Vivo

8 Global Gene Therapy Market, By Application

  • 8.1 Introduction
  • 8.2 DMD (Duchenne Muscular Dystrophy)
  • 8.3 Neurological Diseases
  • 8.4 Cancer
  • 8.5 Hepatological Diseases
  • 8.6 Rare Diseases
  • 8.7 Oncological Disorders
  • 8.8 Acute Lymphoblastic Leukemia (ALL)
  • 8.9 Peripheral arterial disease
  • 8.10 Other Applications

9 Global Gene Therapy Market, By End User

  • 9.1 Introduction
  • 9.2 Cancer Institutes
  • 9.3 Hospitals
  • 9.4 Research Institutes
  • 9.5 Other End Users

10 Global Gene Therapy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen Inc.
  • 12.2 Biogen Inc.
  • 12.3 Bluebird Bio Inc.
  • 12.4 Gilead Sciences Inc.
  • 12.5 Novartis AG
  • 12.6 F. Hoffmann-La Roche Ltd
  • 12.7 UniQure NV
  • 12.8 Abeona Therapeutics Inc.
  • 12.9 Generation Bio
  • 12.10 Poseida Therapeutics
  • 12.11 Astellas Pharma
  • 12.12 Voyager Therapeutics Inc.
  • 12.12 Jazz Pharmaceuticals, Inc
  • 12.14 GlaxoSmithKline plc
  • 12.15 Spark Therapeutics Inc
  • 12.16 Sarepta Therapeutics
  • 12.17 Orchard Therapeutics
  • 12.18 Shenzhen SiBiono GeneTech
  • 12.19 Shanghai Sunway Biotech Co. Ltd.
  • 12.20 CRISPR Therapeutics AG

List of Tables

  • Table 1 Global Gene Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Gene Therapy Market Outlook, By Vector (2021-2030) ($MN)
  • Table 3 Global Gene Therapy Market Outlook, By Non-Viral Vectors (2021-2030) ($MN)
  • Table 4 Global Gene Therapy Market Outlook, By Oligonucleotides (2021-2030) ($MN)
  • Table 5 Global Gene Therapy Market Outlook, By Other Non-Viral Vectors (2021-2030) ($MN)
  • Table 6 Global Gene Therapy Market Outlook, By Viral Vectors (2021-2030) ($MN)
  • Table 7 Global Gene Therapy Market Outlook, By Retro Viral Vectors (2021-2030) ($MN)
  • Table 8 Global Gene Therapy Market Outlook, By Adeno-Associated Virus Vectors (2021-2030) ($MN)
  • Table 9 Global Gene Therapy Market Outlook, By Lentiviral Vector (2021-2030) ($MN)
  • Table 10 Global Gene Therapy Market Outlook, By Herpes Virus Vector (2021-2030) ($MN)
  • Table 11 Global Gene Therapy Market Outlook, By Other Viral Vectors (2021-2030) ($MN)
  • Table 12 Global Gene Therapy Market Outlook, By Gene Type (2021-2030) ($MN)
  • Table 13 Global Gene Therapy Market Outlook, By Antigen (2021-2030) ($MN)
  • Table 14 Global Gene Therapy Market Outlook, By Cytokine (2021-2030) ($MN)
  • Table 15 Global Gene Therapy Market Outlook, By Tumor Suppressor (2021-2030) ($MN)
  • Table 16 Global Gene Therapy Market Outlook, By Suicide (2021-2030) ($MN)
  • Table 17 Global Gene Therapy Market Outlook, By Deficiency (2021-2030) ($MN)
  • Table 18 Global Gene Therapy Market Outlook, By Growth factors (2021-2030) ($MN)
  • Table 19 Global Gene Therapy Market Outlook, By Receptors (2021-2030) ($MN)
  • Table 20 Global Gene Therapy Market Outlook, By Other Gene Types (2021-2030) ($MN)
  • Table 21 Global Gene Therapy Market Outlook, By Delivery Method (2021-2030) ($MN)
  • Table 22 Global Gene Therapy Market Outlook, By In Vivo (2021-2030) ($MN)
  • Table 23 Global Gene Therapy Market Outlook, By Ex Vivo (2021-2030) ($MN)
  • Table 24 Global Gene Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 25 Global Gene Therapy Market Outlook, By DMD (Duchenne Muscular Dystrophy) (2021-2030) ($MN)
  • Table 26 Global Gene Therapy Market Outlook, By Neurological Diseases (2021-2030) ($MN)
  • Table 27 Global Gene Therapy Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 28 Global Gene Therapy Market Outlook, By Hepatological Diseases (2021-2030) ($MN)
  • Table 29 Global Gene Therapy Market Outlook, By Rare Diseases (2021-2030) ($MN)
  • Table 30 Global Gene Therapy Market Outlook, By Oncological Disorders (2021-2030) ($MN)
  • Table 31 Global Gene Therapy Market Outlook, By Acute Lymphoblastic Leukemia (ALL) (2021-2030) ($MN)
  • Table 32 Global Gene Therapy Market Outlook, By Peripheral arterial disease (2021-2030) ($MN)
  • Table 33 Global Gene Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 34 Global Gene Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Global Gene Therapy Market Outlook, By Cancer Institutes (2021-2030) ($MN)
  • Table 36 Global Gene Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 37 Global Gene Therapy Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 38 Global Gene Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.